INVESTIGADORES
SOCIAS Sergio Benjamin
congresos y reuniones científicas
Título:
New therapeutic perspective for Parkinson?s disease: Doxycycline inhibits the formation of α-synuclein toxic species
Autor/es:
GONZALES LIZARRAGA, MF; SOCIAS, S.B.; AVILA C.; TORRES-BUGEAU C.; BARBOSA L.; BINOLFI A.; ITRI R.; SEPULVEDA DIAZ, J.; PAPY GARCÍA D.; CHEHÍN R.; RAISMAN VOZARI R.
Lugar:
Copenhague
Reunión:
Congreso; 10th Forum of Neuroscience; 2016
Institución organizadora:
Federation of European Neuroscience Societies (FENS)
Resumen:
The aggregation of α-synuclein is considered the main pathogenic event in many neurological disorders known as synucleinopathies, such as Parkinson?s disease (PD). While the basis of neurotoxicity of α-synuclein remains controversial, it is now accepted that certain oligomeric species generated during α-synuclein amyloid self-assembly are most likely key players in the initiation and spreading of the pathology. In addition, compelling evidence shows that α-synuclein aggregation can also trigger oxidative stress, mitochondrial dysfunction, and neuro-inflammation and sometimes vice versa, suggesting that these processes could be intertwined fostering a vicious circle with fatal consequences for neurons. In animal models of PD, doxycycline has been shown to exert neuroprotection. It has been proposed that the mechanism underlying this effect is the ability of doxycycline to diminish neuro-inflammation. Since treatment with anti-inflammatory compounds alone has not proved to be enough to prevent neurodegeneration, we propose that doxycycline might have an additional target. The aim of this work is explore the effect of doxycycline on α-synuclein aggregation, seeding and α-synuclein mediated toxicity.